BVNKF:OTCMKTS
Bavarian Nordic A/S
36,06 $
0,00%
(0,00) 1D
8 қаз., 15:46:25 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNKF...
Mkt. cap
2,77 млрд
Avg. vol.
14,00
Volume
0,00
52-wk high
37,22 $
52-wk low
27,69 $
Beta
1,46
Shares outstanding
79,26 млн
No. of employees
2 мың
Mkt. cap
2,77 млрд
Avg. vol.
14,00
Volume
0,00
52-wk high
37,22 $
52-wk low
27,69 $
Beta
1,46
Shares outstanding
79,26 млн
No. of employees
2 мың
News stories
From web sources and news partners
Stock Titan
·
9 минут бұрын
Two governance gaps trigger a Nasdaq notice for Better Home & Finance (NASDAQ: BETR)
MarketWatch
·
4 минут бұрын
Why Dell’s stock was one of the S&P 500’s biggest laggards on Wednesday
TradingView
·
25 минут бұрын
Taoping Inc. (TAOP) Receives Nasdaq Bid-Price Deficiency Notice
Seeking Alpha
·
2 сағат бұрын
Nasdaq tumbles 2%, and these 10 stocks have fueled the selloff
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1,91 мың
Founded1992 ж. 01 шіл.
Headquarters-
Sector-
Websitebavarian-nordic.com